Many dog owners are familiar with the FDA warning and the concerning side effects associated with the new arthritis drug Librela, also known as bedinvetmab. Developed by Zoetis, a Pfizer spinoff specializing in animal health, Librela first appeared in Europe in 2020 and gained FDA approval in 2023, with US sales commencing in May of the same year. While initial studies indicated positive outcomes in pain relief and mobility for dogs receiving Librela, reports of mild side effects such as appetite loss, injection site pain, and skin irritation emerged. However, with over 40,000 documented adverse reactions including urinary and kidney issues, seizures, and fatalities, concerns have been raised about the drug’s safety profile.
Critics point to the FDA’s approval process, citing a small study in Europe and data from only 135 US dogs as the basis for regulatory clearance, despite subsequent administration of millions of doses. Allegations of underreporting adverse events by the manufacturer have surfaced, calling into question the accuracy of safety claims. Despite warnings from some veterinary groups, others have downplayed risks, potentially influenced by financial support from Zoetis. The broader issue of pharmaceutical companies rushing new products to market with limited testing and regulatory oversight is highlighted, emphasizing the need for informed decision-making by pet owners when considering novel treatments. Vigilance, research, and open communication with your veterinarian are essential in safeguarding your dog’s well-being when navigating the complexities of emerging medications.
Some diseases do not have cures, and the mere fact that a company has produced a new drug and tested it on a few dogs does not guarantee its safety as a viable treatment option.
